



Akasaka Intercity, 1-11-44, Akasaka, Minato-ku, Tokyo 107-0052
Phone +81-3-6299-8905 Fax +81-3-6299-8922
<https://corporate.m3.com> pr@m3.com

Launch of Internal Corporate Venture Capital Fund “1P1Y (1 Person 1 Yen) Fund”
~ Acceleration of 7P Projects through 10 Billion Yen Investment ~

M3, Inc (Headquarters: Tokyo, Japan; URL: <https://corporate.m3.com/>; CEO: Itaru Tanimura; “M3” below) has announced the establishment of a new internal CVC* fund, “1P 1Y (1 Person 1 Yen) Fund”, to accelerate the expansion of the “7P Projects”.

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 280,000+ physician members in Japan, an equivalent to 90% of the physicians in the country, and offers marketing and clinical trial services. Recent business expansion have been in areas such as AI diagnostic tool development, genome diagnostics provision, and stroke rehabilitation centers, no longer limited to pharmaceutical marketing. “7P Projects” aim to integrate such businesses in order to provide holistic solutions for multiple issues within individual therapeutic areas.

To date, M3 has invested in roughly 30 venture companies that presented synergies with M3, with successful IPOs in companies such as SMS Co., Ltd., Raksul Inc., and StemRim, Inc.

In order to accelerate the expansion of the “7P Projects” to ultimately realize M3’s corporate mission, M3 has newly allocated an investment line of 10 billion yen towards initiation of the CVC fund. Investment sizes will be increased compared to previous investments, to average a few hundred million yen and up to a maximum of roughly 2 billion yen each, in order to expedite initiatives with venture companies and pharmaceutical companies under “7P Projects” operations. Furthermore, M3’s ecosystem, the diverse domestic and global resources spanning from development to marketing support and involving various stakeholders such as healthcare workers to patients, will also be utilized to support the growth of its investments as well as the creation of new businesses.


* CVC: Corporate Venture Capital

<Overview of In-House CVC Fund>

Name	1P1Y (1 Person 1 Yen) Fund
Origin of Name	Embodies M3's mission, "Using the Internet to enable as many people as possible to live happier, healthier lives, and reduce, as much as possible, unnecessary medical costs"
Total Investment Line	10 billion yen
Investment Region	Domestic and Global
Investment Target	Venture companies, listed companies, pharmaceutical and medical device pipelines, others.
Investment Themes	AI, medical devices (including software), advanced medical technologies, rare diseases, healthcare management
Investment Size	Average of 1-2 hundred million yen per company to a maximum of approximately 2 billion yen

<Advantages of the 1P1Y Fund>

Advantages of the 1P1Y Fund



Realize high returns through maximization of m3.com resources and extensive investment track record

M3's Venture Support Ecosystem

